Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Solicitation / RFP / RFQ

This Request for Quotation (RFQ) seeks price quotes for pharmaceutical agents to be considered for placement on the Department of Defense (DOD) Uniform Formulary (UF). The DOD is required by law to establish an effective pharmacy benefits program for the Military Health System (MHS). This process involves the DOD Pharmacy and Therapeutics (P&T) Committee evaluating clinical and cost-effectiveness of pharmaceutical agents.

• Manufacturers are to submit quotes for pharmaceutical agents.

• Quotes will be considered for two instruments: Uniform Formulary Blanket Purchase Agreements (UF BPA) for Military Treatment Facilities (MTF) and TRICARE Mail Order Pharmacy (TMOP), and Uniform Formulary Additional Discount Program (UF ADP) for refunds from TRICARE retail network pharmacies.

• Companies must submit a NDC Price List with each quote.

• Quotes must include all NDC-11s for the marketed pharmaceutical agent.

• Pricing must be held valid for 180 days.

• Companies must have an existing FSS contract/Interim Agreement for quoted agents.

• The document outlines the process for establishing UF BPAs and UF ADPs.

• The period of performance for UF BPAs is until the drug class is reevaluated or terminated.

• Pricing is subject to change based on FSS contract updates and PPI.

• RFQ Dates:

  • Posting Date: January 9, 2026
  • Pre-Quotation Teleconference: January 14, 2026
  • Quotes Due: January 26, 2026
  • Responses to Clinical Questions Due: January 26, 2026
  • P&T Committee Meeting: February 4-5, 2026

• Submission: Quotes and NDC Price Lists are to be submitted electronically to the RFQ Point of Contact.

• Evaluation: The DOD P&T Committee will evaluate quotes based on clinical effectiveness, cost-effectiveness, and proposed pricing to determine placement on the UF, BCF, or ECF.

• Not explicitly stated, but the process is for pharmaceutical manufacturers.

• A pre-quotation teleconference will be held on January 14, 2026.

• One-on-one appointments with the Industry Technical Liaison are available upon request.

• The document includes appendices for Manufacturer Quote Submission Checklist, UF BPA, UF ADP, and NDC Price List.

Forms / Attachments / Pricing Sheets

This document contains pricing information and appendices related to Glaucoma Agents for the February 2026 DoD P&T Meeting. It includes a Blanket Purchase Agreement (BPA) Appendix, an Additional Discount Program (ADP) Appendix for non-FAMP discounts, and an ADP Appendix for WAC discounts.

• BPA Appendix: Lists NDC Numbers, Drug Names, Strengths, Dosage Forms, Package Sizes, and pricing scenarios for Glaucoma Agents. It indicates "NO QUOTE" for certain scenarios and highlights the need to confirm intent not to submit a quote if cells are highlighted red.
• ADP (non-FAMP Discount) Appendix: Details pricing and refund calculations based on non-Federal Acquisition Regulation (non-FAMP) prices. It outlines formulas for calculating total retail refunds and specifies that the quoted additional refund percentage remains static, but the annual non-FAMP may change.
• ADP (WAC Discount) Appendix: Provides pricing based on Wholesale Acquisition Cost (WAC) for products without a Federal Ceiling Price (FCP). It explains that the WAC discount percentage is static for the agreement's life.
• Common Information: All appendices reference a P&T Committee Meeting on February 4-5, 2026, and a quotes due date of January 26, 2026. They also include class notes regarding review at the P&T Committee meeting, potential Prior Authorization (PA), special reimbursement methods, and Step Therapy Addendums.

This document is crucial for bidders interested in supplying Glaucoma Agents. It outlines the specific pricing structures (BPA, non-FAMP, WAC), refund calculations, and submission deadlines. Bidders must review the relevant appendix and pricing scenarios to determine their quoting strategy and ensure timely submission of quotes and executed signature pages. The "NO QUOTE" indications and red highlighting instructions are critical for understanding submission requirements.

Forms / Attachments / Pricing Sheets

This document contains pricing information and appendices related to the Uniform Formulary (UF) for the February 2026 DoD P&T Meeting. It includes Blanket Purchase Agreement (BPA) Appendices and Additional Discount Program (ADP) Appendices for both non-FAMP and WAC discounts, specifically for the 'METABOLIC AGENTS - MISCELLANEOUS' class and 'REPLACEMENT ENZYMES' subclass.

• BPA Appendix: Lists drug names, strengths, dosage forms, package sizes, and pricing scenarios (Uniform Formulary, Non-Formulary). It indicates "NO QUOTE" for specific scenarios and prompts confirmation if a quote will not be submitted.
• ADP Appendix (non-FAMP Discount): Details drug information, formulary categories (Tier 2, Tier 3), and pricing components including Non-FAMP Price, Additional Offered Refund, Current Annual Federal Ceiling Price, Standard Refund, and Total Calculated Retail Refund. It also provides notes on how these are calculated and the P&T Committee review process.
• ADP Appendix (WAC Discount): Similar to the non-FAMP discount, but focuses on Wholesale Acquisition Cost (WAC) pricing, WAC discount percentages, and total calculated retail refunds per package. It clarifies that WAC is used for products without an FCP.
• Common Information: All sections note the P&T Committee Meeting date (February 4-5, 2026) and a quotes due date of January 26, 2026. They also include class notes regarding potential Prior Authorization (PA), special reimbursement methods, and step therapy considerations. Manufacturers are reminded to submit fully executed signature pages with quotes.

This document is crucial for bidders providing metabolic agents, specifically replacement enzymes. It outlines the pricing structure, discount programs (non-FAMP and WAC), and submission requirements for quotes. Bidders must understand these pricing appendices to accurately prepare and submit their quotes by the January 26, 2026 deadline. The information on formulary tiers, discounts, and potential P&T Committee actions directly impacts pricing strategies and potential contract terms.

Forms / Attachments / Pricing Sheets

This document contains several appendices related to the Uniform Formulary (UF) for the February 2026 DoD P&T Meeting, specifically for "METABOLIC AGENTS - MISCELLANEOUS." It includes a Blanket Purchase Agreement (BPA) Appendix, an Additional Discount Program (ADP) Appendix with both non-FAMP and WAC discount considerations, and a WAC Discount Appendix. These documents outline pricing structures, formulary scenarios, and discount requirements for pharmaceutical agents.

• BPA Appendix: Details pricing per NDC, strength, dosage form, and package size for Uniform Formulary and Non-Formulary agents. It indicates "NO QUOTE" for certain scenarios and highlights that red-highlighted cells require confirmation of intent not to submit a quote.
• ADP (non-FAMP) Appendix: Outlines refund calculations based on non-FAMP (non-Federal Acquisition Regulation) prices and Federal Ceiling Prices (FCP). It specifies tiers (Tier 2, Tier 3) and requires manufacturers to provide additional offered refunds.
• ADP (WAC) Appendix: Details pricing based on Wholesale Acquisition Cost (WAC) for products without an FCP. It outlines WAC discount percentages and total calculated retail refunds.
• Common Information: All appendices reference the February 4-5, 2026 P&T Committee Meeting and a quotes due date of January 26, 2026. They also include class notes regarding potential Prior Authorization (PA), special reimbursement methods, and step therapy considerations. Manufacturers are reminded to submit fully executed signature pages with quotes.

This document is crucial for bidders offering "METABOLIC AGENTS - MISCELLANEOUS." It provides the framework for pricing, discount submissions, and refund calculations required for participation in the DoD's Uniform Formulary. Bidders must pay close attention to the "Quotes due" date (January 26, 2026) and the specific pricing and discount structures outlined in the BPA, non-FAMP, and WAC appendices to prepare accurate and compliant quotes. The "Class Notes" and "Step Therapy Addendum" also provide important context regarding formulary placement and potential reimbursement policies.

Forms / Attachments / Pricing Sheets

This document contains pricing information and appendices related to the Uniform Formulary (UF) Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) for Nephrology Agents Miscellaneous. It outlines pricing structures and discount programs relevant to the February 2026 DoD P&T Meeting.

• BPA Sheet: Lists NDC numbers, drug names, strengths, dosage forms, package sizes, and pricing scenarios for the Uniform Formulary. It specifies a quote due date of January 26, 2026, and indicates "NO QUOTE" for certain scenarios, with instructions to confirm intent if a cell highlights red.
• ADP (non-FAMP Discount) Sheet: Details pricing and refund calculations for the Additional Discount Program based on non-FAMP (non-Federal Acquisition Regulation) prices. It includes formulas for calculating total retail refunds and specifies a quote due date of January 26, 2026.
• ADP (WAC Discount) Sheet: Outlines pricing and discount calculations based on Wholesale Acquisition Cost (WAC). It defines how WAC is obtained and used for pricing, with a static discount percentage for the agreement's life. The quote due date is also January 26, 2026.
• Class Notes: Across all sheets, notes indicate that these agents will be reviewed at the February 4-5, 2026 P&T Committee Meeting. Prior Authorization (PA) may apply, and agents may be subject to special reimbursement methods or exclusion from the TRICARE pharmacy benefit program. Agents not submitted or selected for RFQ may be designated non-step preferred.

This document is crucial for potential bidders offering nephrology agents. It provides the framework for pricing, discounts, and refund calculations under the Uniform Formulary and Additional Discount Programs. Bidders must pay close attention to the quote due date (January 26, 2026) and the specific pricing and discount structures outlined for each scenario to prepare accurate quotes and understand potential reimbursement terms.

Other / Unclassified

This document is a notice regarding the DoD Formulary Placement of FDA Newly Approved Innovator Drugs. It clarifies the process for placing newly approved drugs on the uniform formulary, as outlined in a Final Rule published in the Federal Register on July 27, 2015. The Pharmacy and Therapeutics (P&T) Committee has up to 120 days to recommend tier placement.

• Drug Evaluation: Innovator drugs evaluated are FDA-approved medications under BLA or NDA with specific chemical types (Type 1, 2, 3, 4). The P&T Committee may also select other NDA chemical type innovator drugs.
• Status of New Drugs: Drugs approved by the FDA on or after August 26, 2015, will initially be assigned a pending status and treated as non-formulary.
• Consideration Timeline: Drugs approved 30 days or less before a P&T Committee meeting will be considered at the subsequent quarterly meeting.
• Pricing and Solicitations: The government will solicit Uniform Formulary Blanket Purchase Agreement (UF BPA) and Additional Discount Program (UF ADP) quotes. Manufacturers will have three solicitation windows to submit price concessions.
• Tier Designation: Drugs will be designated for Tier 1, 2, 3, or 4/Not Covered based on clinical and cost-effectiveness information available at the quarterly meeting.
• Information Posting: Drugs to be reviewed will be posted on the health.mil/pandt page approximately 30 days before the meeting.
• Distribution and Pricing Agreement (DAPA): Pharmaceutical manufacturers are not obligated to provide a DAPA, but information on establishing one can be obtained from the Defense Logistics Agency (DLA).
• Formulary Access: Innovator drugs are generally designated as Tier 3 and available at retail pharmacies with a Tier 3 copay, unless medical necessity criteria are met for a 2nd tier copay.
• Presentations: DoD will not entertain innovator drug clinical presentations due to the volume of newly approved drugs.

Form / Attachment / Pricing Sheet

This document, "Price Appendix FAQ," provides frequently asked questions and instructions for completing pricing appendices related to an opportunity. It guides bidders on how to fill out spreadsheets for different pricing scenarios, including BPA, ADP (non-FAMP Discount), and ADP (WAC Discount).

• BPA (Blanket Purchase Agreement): Instructions on filling out yellow cells, auto-population of fields based on Package Size, and how to indicate non-submission of a quote (red highlighting).
• ADP (non-FAMP Discount): Guidance on inputting non-FAMP price and Current Annual Federal Ceiling Price, auto-population, and how to indicate a 0.0000% Additional offered refund.
• ADP (WAC Discount): Explanation of WAC usage for products without a FCP, instructions for inputting WAC price, and how to indicate a 0.0000% WAC Discount.
• General Instructions: All sections emphasize reading "Formulary Notes" for P&T committee decision-making processes, filling only yellow cells, and auto-calculation of certain fields.
• NDC Limits: Bidders are provided tables for 10 different National Drug Codes (NDCs). If more are needed, they should contact the POCs listed in the RFQ document.

This document is crucial for bidders to accurately prepare and submit their pricing information. It clarifies how to use the provided spreadsheets, what data to input, how certain fields are calculated, and how to indicate specific pricing decisions. Failure to follow these instructions could lead to incomplete or incorrect submissions. Bidders should pay close attention to the specific instructions for each pricing category (BPA, ADP non-FAMP, ADP WAC) and the limits on the number of NDCs they can initially input.